Bristol-Myers Squibb (BMS) has been dwelling in turbulent waters due to a multi-million dollar liability case concerning Plavix marketing in Hawaii. Sanofi shares the liability, now standing at $916 million. Despite the significant legal setback, BMS presented extensive data from over 130 studies encompassing 25 diseases at the ASCO & EHA, highlighting their robust research activity. The company simultaneously launched a 10-year drug access plan aimed at expanding medication access in lower-income countries. Young-generation actor Taye Diggs joined hands with BMS to challenge schizophrenia stereotypes and generate awareness about schizophrenia, aiming to empower affected individuals.
The company has faced some criticism over data breach impacting customers’ information. However, the company has shown resilience by announcing a new 10-year strategy to reach patients in low- and middle-income countries, furthering their commitment to inclusivity and expanded medication access globally. They also plan to launch 16 new products by 2030, according to their CEO, demonstrating their continued innovation amidst the challenges. On another front, BMS failed to triumph over AstraZeneca in stage 3 lung cancer, a setback undoubtedly affecting its market position.
Bristol-Myers Squibb News Analytics from Wed, 20 Dec 2023 08:00:00 GMT to Thu, 23 May 2024 21:05:00 GMT - Rating -6 - Innovation 2 - Information 4 - Rumor -3
